Agilent Announces ProZyme Acquisition
Agilent Technologies has announced that it has entered into a definitive agreement to acquire the privately held ProZyme, Inc., a provider of glycan analysis reagents, kits, and standards.
Agilent Technologies (Santa Clara, California, USA) has announced that it has entered into a definitive agreement to acquire the privately held ProZyme, Inc. (Hayward, California, USA), a provider of glycan analysis reagents, kits, and standards. The acquisition will expand Agilent’s portfolio of biopharmaceutical consumables in the growing glycan market.
Founded in 1990, ProZyme is a developer and manufacturer of glycan reagents, kits, and standards, which are required for efficient sample preparation in the analysis of free glycans. Glycobiology, which is the study of the structure, function, and biology of carbohydrates, also called glycans, is a fastâgrowing and important field of study in life sciences. Glycans play diverse roles in biotherapeutics, novel drug development, the study of bacterial physiology, and proteomics research.
“Glycan analysis is essential to the discovery, development, and quality control testing of the ever-growing pipeline of biotherapeutic drug products,” said Padraig McDonnell, Vice President and General Manager of Agilent’s Chemistries and Supplies Division. “This acquisition provides greater scale to our biopharma consumables business and enhances our value proposition by enabling complete glycan liquid chromatography and mass spectrometry workflow solutions.”
For more information, please visit www.agilent.com and www.prozyme.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
